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Simple Summary: Blood contains proteins which have interest as products that may regulate
immune function. For this reason some protein-based products are currently used as nutritional
supplements for animals, for instance two porcine concentrates, spray dried serum (SDS), and an
immunoglobulin concentrate (IC). These products have shown to protect against colonic inflammation
in rodents. In the present study we characterize the ability of these products to modulate immune
function in isolated cells, namely intestinal epithelial cells (IEC18 cells) and rat spleen cells. Our
data indicate that both porcine protein concentrates indeed alter immune cell function, based on the
secretion of the modulators known as cytokines. In intestinal epithelial IEC18 cells they promoted
the secretion of GROα and MCP-1 cytokines. In spleen cells they mainly inhibited the production of
TNF, a key proinflammatory cytokine. In addition, the IC product augmented the release of IL-10, an
anti-inflammatory cytokine. Taken together, our data indicate that the immunomodulatory effects
observed in vivo are consistent with the direct actions of the protein concentrates on epithelial cells,
T lymphocytes, and monocytes.
Abstract: Serum protein concentrates have been shown to exert in vivo anti-inflammatory effects.
Specific effects on different cell types and their mechanism of action remain unraveled. We aimed to
characterize the immunomodulatory effect of two porcine plasma protein concentrates, spray dried
serum (SDS) and an immunoglobulin concentrate (IC), currently used as animal nutritional supple-
ments with established in vivo immunomodulatory properties. Cytokine production by the intestinal
epithelial cell line IEC18 and by primary cultures of rat splenocytes was studied. The molecular path-
ways involved were explored with specific inhibitors and gene knockdown. Our results indicate that
both products induced GROα and MCP-1 production in IEC18 cells by a MyD88/NF-κB-dependent
mechanism. Inhibition of TNF production was observed in rat primary splenocyte cultures. The
immunoglobulin concentrate induced IL-10 expression in primary splenocytes and lymphocytes.
The effect on TNF was independent of IL-10 production or the stimulation of NF-kB, MAPKs, AKT,
or RAGE. In conclusion, SDS and IC directly regulate intestinal and systemic immune response in
murine intestinal epithelial cells and in T lymphocytes and monocytes.
Keywords: immunoglobulin concentrate; serum protein concentrate; Toll-like receptors; TLR4; Myd88
1. Introduction
Protein products have interest for immunomodulation and the promotion of health
beyond their nutritional properties, i.e., as functional foods or nutritional supplements.
Thus, spray dried plasma (SDP) has been used as a dietary supplement to promote animal
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growth. This approach has also been reported to exert protection against rotavirus diarrhea
in pigs [1]. Several of these concentrates from bovine or porcine origin have been shown to
affect the host response in animal models of intestinal and lung inflammation [2–8]. Namely,
in young and senescent animals challenged by Staphylococcus aureus enterotoxin B, dietary
supplementation with functional proteins from SDP of porcine origin has been shown
to modulate the intestinal barrier and defense mechanisms, thereby reducing the degree
of gut-associated lymphoid tissue activation [2,8,9]. A dietary supplement containing
over 90% bovine serum protein (>50% immunoglobulins) reduces inflammatory markers
and tissue damage in mice models of colitis [10–12] and mucositis [13]. Simultaneous
protection against lung and colon inflammation has been documented for porcine SDP [14].
Further, the latter has been recently shown to exert neuroprotective activity in a senescence
murine model [15] and partial protection against intraperitoneal LPS challenge in pregnant
mice [16]. On the other hand, immunoglobulin concentrates from porcine or ovine blood
display neutralizing activity in vitro against lipopolysaccharide (LPS) and pathogenic
Gram-positive and Gram-negative bacteria [17,18]. They have been also used to transfer
passive immunity as components of colustrum supplements or replacers [19].
Besides animal studies, clinical trials have shown benefit of immunoglobulin concen-
trate (IC) administration to patients with irritable bowel syndrome, reducing symptoms
(improved stool consistency and frequency, pain, and bloating) and cytokine produc-
tion [20]. Immunoglobulin concentrates have been also shown to be effective in the man-
agement of enteropathy associated with diarrhea-predominant in irritable bowel syndrome
and human immunodeficiency virus infection [21,22], or diarrhea produced by E. coli or
Shigella [23,24]. Supplementation of infant formula with an IC protects against diarrhea in
infants [25]. The antibodies contained in these products resist digestion in humans and
retain bioactivity [26], as shown for a Clostridium difficile IC [27,28]. These studies have
shown that IC may act by binding antigens in the intestinal lumen [29].
Despite the available in vivo evidence there are a few mechanistic studies dealing with
the actions of these protein products on cells. Whey proteins have been shown to stimulate
the production of proinflammatory cytokines (IL-6 and IL-8) by the intestinal epithelial
cell line Caco-2 [30]. Our study aims to describe the molecular mechanisms involved in
the modulation of the immune system by two plasma concentrates from porcine origin,
namely spray-dried serum (SDS) and IC. The intestinal cell line IEC18, spleen cells and
primary cultures of spleen T lymphocytes and monocytes were used. Signal transduction
pathways involved have also been investigated.
2. Materials and Methods
2.1. Animals
Thirty-two female Wistar rats (190–220 g) obtained from Janvier Labs (Le Gen-est-
Saint-Isle, France) were housed in makrolon cages, maintained with a 12 h light–dark cycle
and fed standard rodent chow (Panlab A04, Panlab, Barcelona, Spain) and water ad libitum
throughout the experiment. All animal experiments were carried out in strict accordance
with the ARRIVE guidelines and the EU Directive 2010/63/EU for animal experiments,
and were approved by the local ethical committee (ref. 01/03/2017/029).
2.2. Materials
Except indicated otherwise, all chemicals were obtained from Sigma-Aldrich (Madrid,
Spain). Protein concentrates were supplied by APC Europe, S.L.U. (Granollers, Spain). SDS
was obtained after fibrinogen precipitation in acid conditions, then the resulting serum was
neutralized to pH 6. IC was obtained from porcine serum following the method described
by Lee et al. [31] using sodium hexametaphosphate to obtain an immunoglobulin enriched
fraction that was neutralized to pH 7. Both products were ultrafiltered and diafiltered
through a 30 kD membrane and the retentate was dried in a Buchi 190 Mini Spray Drier
(Büchi Labortechnick AG, Flawil, Switzerland).
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2.3. Primary Splenocytes
Primary splenocytes were obtained from rats sacrificed by cervical dislocation by me-
chanical dissection as described before [32] and cultured at 106 cells/mL with or without
lipopolysaccharide (LPS, E. coli 055:B5, 1 µg/mL). The culture medium was Roswell Park
Memorial Institute (RPMI) supplemented with 100 mg/L streptomycin, 100,000 U/L peni-
cillin, 2.5 mg/L amphotericin B and 50 µM β-mercaptoethanol. The cells were maintained
at 37 ◦C in standard culture conditions.
2.4. IEC18 Experiments
Non-transformed rat small intestinal epithelial IEC18 cells (ECACC 88011801) (pas-
sages 25–50) were obtained from the Cell Culture Service of the University of Granada
and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing fetal bovine
serum (10%) until confluency (4–5 days after seeding). All experiments were carried out
with DMEM containing no fetal bovine serum, except for some groups as a reference. The
control group received PBS. Concentration response curves were initially obtained with
cells incubated for 24 h with the protein concentrates. MCP-1 and GROα secretion was
measured by ELISA in cell media (Becton Dickinson, Madrid, Spain, and R&D Systems,
Minneapolis, MN, sensitivity 10 and 1.3 pg/mL).
In order to explore downstream signaling pathways, IEC18 confluent monolayers
were exposed to Bay 11-7082 (10 µM), a selective inhibitor of IκB-α phosphorylation that
blocks the NF-κB signaling pathway, or wortmannin (1 µM), an inhibitor of phosphatidyli-
nositol 3 kinase (PI3K) phosphorylation that inhibits the AKT signaling pathway. MAPK
inhibitors SB203580 (for p38, 10 µM), PD98059 (for ERK1/2, 10 µM), or SP600125 (for JNK,
10 µM) were also added to the cell cultures to selectively inhibit their phosphorylation.
All the inhibitors were dissolved in dimethyl sulfoxide (DMSO) and were added to the
culture medium 2 h before the treatment with SDS or IC. DMSO was also added to the
control group.
2.5. Gene Silencing
In some experiments IEC18 with MyD88 or TLR4 siRNA gene knockdown were
used in order to assess the involvement of these signaling molecules in the effects of the
products as previously described [33]. In all cases the cell culture medium was free of fetal
bovine serum.
2.6. Splenocyte Experiments
Rat splenocytes were cultured at 105 cells/100 µL and treated with SDS/IC in basal
conditions or under exposure to LPS. The control group received PBS. Cell culture medium
was collected after 24 h, cleared by centrifugation, and frozen at −80 ◦C until assayed for
cytokine content by commercial ELISAs (Beckton Dickinson, Madrid, Spain). In all the
experiments, samples were run in triplicate and results are expressed as cytokine concen-
tration (pg/mL). Hence n = 6 per condition since the experiments were performed twice.
In some experiments NF-κB and MAPK inhibitors were applied as above and the
inhibitor of the receptor for advanced glycation end products (RAGE), FPS-ZM1-1, was
also used. The involvement of the CD40/IL-10 pathway was assessed with an IRAK1/4
inhibitor (1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole) and blocking
monoclonal antibodies (anti-CD154 and anti-IL-10, Thermo Fisher Scientific, Waltham, MA,
USA), which were added to cells 2 h before other treatments.
2.7. Isolation of Splenic T Lymphocytes and Monocytes
Primary T lymphocytes and monocytes were obtained from rat spleen by negative
magnetic separation using Miltenyi Biotec microbeads (Madrid, Spain) and columns and
BD Biosciences monoclonal antibodies (anti-CD11b, anti-CD161, anti-CD45RA and anti-
CD3, anti-CD161, anti-CD45RA, respectively) [32]. Separation and purification protocols
were set up and validated by flow cytometry, using FACS CaliburTM (BD Biosciences,
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San Jose, CA, USA). T cell purity was typically >95%. Cells were cultured as described for
splenocytes above.
2.8. Statistical Analysis
The data shown are expressed as mean ± SEM and are representative of 2–3 experi-
ments, except those displayed in Figures 1C,D and 6. Means were tested for significant
differences by one way or two way analysis of variance as appropriate followed by least
significant difference tests on comparisons with the control and/or basal groups. p < 0.05
was the significance threshold. All analyses were carried out with GraphPad Prism 6
(San Diego, CA, USA).
3. Results
3.1. IC and SDS Induce Proinflammatory Cytokine Production in IEC18 Cells through a Pathway
Involving the Activation of NF-κB
Culturing IEC18 cells, an intestinal epithelial cell line, with IC or SDS induced the
production of the proinflammatory cytokines GROα and MCP-1 (Figure 1A,B, respectively).
The magnitude of cytokine induction was similar for both products in the case of MCP-1,
but SDS was a less powerful inducer of GROα than IC.
To characterize the connection of the key transcription factor NF-κB with the effect of IC
and SDS on MCP-1, Bay-11-7082 (an inhibitor of IκB-α phosphorylation and of the ubiquitin
system) was used. Our results indicate that NF-κB is clearly involved in the observed effects
since its inhibition abrogated GROα and MCP-1 responses (Figure 1C,D, respectively).
MAPK and AKT are also involved in signal transduction to regulate the immune
response to some extent, particularly in the case of MCP-1. Thus, inhibition of all three
MAPK resulted in 50–70% inhibition of SDS-evoked MCP-1 secretion (significant only for
ERK1/2), while it had no effect under IC stimulation. In turn, GROα was only modestly
affected by the inhibition of JNK and/or ERK1/2. AKT inhibition potentiated IC-evoked
MCP-1 secretion (Figure 1C,D).
3.1.1. TLR4 Is Involved in the Induction of MCP-1 by SDS in IEC18 Cells
To characterize the contribution of TLRs to cytokine stimulation by IC or SDS we
silenced the expression of TLR4 and MyD88, a canonical adaptor downstream of members
of the TLR and IL-1 receptor families, in IEC18 cells. The impact on MCP-1 was assessed
(selected on the basis of higher induction and similar regulation as GROα). Our results
indicate a different mechanism of both products. Thus, silencing TLR4 significantly de-
creased IC-induced MCP-1 release. Nevertheless, a complete abrogation of the effect was
not observed, pointing at a minor involvement of other pathways and/or receptors. In
turn, no effect of TLR4 silencing on the response to SDS was observed, ruling out the
contribution of this receptor. Silencing MyD88 almost entirely inhibited MCP-1 production
evoked by either IC or SDS (Figure 1E), implying the involvement of other receptors that
use MyD88 as an adaptor molecule.
3.1.2. SDS and IC Regulate Cytokine Production in Spleen Cells
The effects of IC and SDS on cytokine production by spleen cells depended on the prod-
uct assayed and the cytokine measured (Figure 2). SDS and especially IC increased spleno-
cyte IFN-γ production in basal conditions in all the concentrations assayed (Figure 2B).
IC also induced IL-10 production, while only a small and inconsistent effect of SDS was
observed (Figure 2C). In contrast, both IC and SDS were found to inhibit basal TNF pro-
duction (Figure 2A). SDS was more potent than IC, as ~50% inhibition was achieved with a
10-fold lower concentration.


















Figure 1. Effect of IC and SDS on cytokine production by IEC18 intestinal epithelial cells. Conflu-
ent monolayers were incubated for 24 h with immunoglobulin concentrate (IC) or spray-dried 
serum (SDS) at 1, 10, and 20 mg/mL and growth-related oncogene α (GROα, (A)) or monocyte 
chemoattractant protein (MCP-1, (B)) were measured in the supernatant by ELISA. To assess the 
mechanism inhibitors for p38 MAPK (SB203580, 10 µM), JNK (SP600125, 10 µM), ERK1/2 
(PD98059, 10 µM), phosphatidylinositol 3-kinase (wortmannin, 1 µM) or NF-κB (Bay 11–7085, 10 
µM) were added to confluent IEC18 intestinal epithelial monolayers 2 h before the addition of IC 
or SDS (10 mg/mL) and GROα (C) and MCP-1 (D) were measured in the 48 h supernatant by 
ELISA. (E) Effect of MyD88 and TLR4 gene silencing on IC and SDS-induced MCP-1 secretion in 
IEC18. Cells were cultured with IC and SDS (both, 10 mg/mL) for 24 h and MCP-1 was measured 
in the culture medium by ELISA. Data are represented as mean ± SEM and are representative of 
two independent experiments (n = 3–4). * p < 0.05 vs. the corresponding Control group; + p < 0.05 
vs. the corresponding Basal (no inhibitor or control vector) group. Results are represented as 
mean ± SEM and are representative of two independent experiments (n = 3). 
To characterize the connection of the key transcription factor NF-κB with the effect 
of IC and SDS on MCP-1, Bay-11-7082 (an inhibitor of IκB-α phosphorylation and of the 
ubiquitin system) was used. Our results indicate that NF-κB is clearly involved in the ob-
served effects since its inhibition abrogated GROα and MCP-1 responses (Figure 1C,D, 
respectively). 
MAPK and AKT are also involved in signal transduction to regulate the immune re-
sponse to some extent, particularly in the case of MCP-1. Thus, inhibition of all three 
MAPK resulted in 50–70% inhibition of SDS-evoked MCP-1 secretion (significant only for 
Figure 1. Effect of IC and SDS on cytokine production by IEC18 intestinal epithelial cells. Confluent
monolayers were incubated for 24 h with immunoglobulin concentrate (IC) or spray-dried serum
(SDS) at 1, 10, and 20 mg/mL and growth-related oncogene α (GROα, (A)) or monocyte chemoat-
tractant protein (MCP-1, (B)) were easured in the supernata t by ELISA. To assess the mechanism
inhibitors for p38 MAPK (SB203580, 10 µM), JNK (SP600125, 10 µM), ERK1/2 (PD98059, 10 µM),
phosphatidylinositol 3-kinase (wortmannin, 1 µM) or NF-κB (Bay 11–7085, 10 µM) were added to
confluent IEC18 intestinal epithelial monolayers 2 h before the addition of IC or SDS (10 mg/mL)
and GROα (C) and MCP-1 (D) were measured in the 48 h supernatant by ELISA. (E) Effect of MyD88
and TLR4 gene silencing on IC and SDS-induced MCP-1 secretion in IEC18. Cells were cultured
with IC and SDS (both, 10 mg/mL) for 24 h and MCP-1 was measured in the culture medium by
ELISA. Data are represented as mean ± SEM and are representative of two independent experiments
(n = 3–4). * p < 0.05 vs. the correspo di g Control group; + p < 0.05 vs. the corresponding Basal (no
inhibitor or control vector) group. Results are represented as mean ± SEM and are representative of
two independent experiments (n = 3).
LPS induced the production of IL-10 and TNF, but not IFN-γ, by splenocytes (Figure 2).
Different effects on IL-10 production were observed when LPS-treated cells were cultured
in the presence of IC or SDS. Thus, SDS was found to inhibit LPS-evoked induction in
a concentration-dependent fashion, while IC produced a small but significant decrease
of IL-10 utput (Figure 2C). In contrast, both products showed a s m lar effect profile
regarding the production of TNF and IFN-γ in the presenc or absence of LPS, clearly
inhibiting the production of TNF while inducing IFN-γ (Figure 2). It is worth noting that
TNF inhibition occurred despite the upregulation by LPS (Figure 2B).
Splenocytes are a mix of several cell types. Among them T lymphocytes and monocytes
are key cells of the immune adaptive and innate response, respectively. We isolated both
cell types from the spleen and used these primary cultures to study the effect of IC and
SDS on cytokine production. As in splenocytes, the addition of either IC or SDS to rat T
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lymphocytes enhanced IFN-γ and IL-10 production and decreased that of TNF (Figure 3).
Monocytes were also isolated and cultured in similar conditions. In this case TNF and
IL-10 production was downregulated in the presence of IC and SDS (Figure 4).
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Figure 2. Effects of immunoglobulin concentrate (IC) and spray dried serum (SDS) on the production
of TNF (A), IFN-γ (B), and IL-10 (C) in basal and LPS-stimulated rat splenocytes. IC and SDS
(1, 10, and 20 mg/mL) were added to the cell culture medium and cytokines were measured in the
supernatant after 24 h by ELISA. LPS (1 µg/mL) was added to stimulate cells 2 h after IC/SDS. Data
are represented as mean ± SEM and are representative of two independent experiments (n = 6).
+ p < 0.05 vs. Control group.
Animals 2021, 11, 807 7 of 14
Animals 2021, 11, x FOR PEER REVIEW 7 of 15 
 
Figure 2. Effects of immunoglobulin concentrate (IC) and spray dried serum (SDS) on the produc-
tion of TNF (A), IFN-γ (B), and IL-10 (C) in basal and LPS-stimulated rat splenocytes. IC and SDS 
(1, 10, and 20 mg/mL) were added to the cell culture medium and cytokines were measured in the 
supernatant after 24 h by ELISA. LPS (1 µg/mL) was added to stimulate cells 2 h after IC/SDS. Data 
are represented as mean ± SEM and are representative of two independent experiments (n = 6). + p < 
0.05 vs. Control group. 
Splenocytes are a mix of several cell types. Among them T lymphocytes and monocytes 
are key cells of the immune adaptive and innate response, respectively. We isolated both 
cell types from the spleen and used these primary cultures to study the effect of IC and SDS 
on cytokine production. As in splenocytes, the addition of either IC or SDS to rat T lympho-
cytes enhanced IFN-γ and IL-10 production and decreased that of TNF (Figure 3). Mono-
cytes were also isolated and cultured in similar conditions. In this case TNF and IL-10 
production was downregulated in the presence of IC and SDS (Figure 4). 
3.1.3. Signal Transduction Pathways Involving NF-κB, MAPK, AKT, or RAGE Do Not 
Contribute to Cytokine Regulation by IC or SPD in Spleen Cells 
Next, we studied the molecular mechanisms involved in the observed responses us-
ing inhibitors of different signal transduction molecules involved in NF-κB, MAPK, AKT, 
or RAGE pathways (Figures 3–5). As expected, the inhibitors downregulated basal cyto-
kine production to various degrees. Nevertheless, inhibitors failed to counteract the ef-
fects of IC or SDS in splenocytes, T lymphocytes, or monocytes, indicating that these path-
ways are not involved in the effect. Since NF-κB is a key factor in the regulation of inflam-
mation we further ruled out its involvement characterizing the effect of both products on 
p65 translocation to the nucleus, however, no induction was observed (Figure 5D). 
 
Figure 3. Effects of immunoglobulin concentrate (IC) and spray dried serum (SDS) on the produc-
tion of TNF (A), IFN-γ (B), and IL-10 (C) by rat lymphocytes. IC and SDS (10 mg/mL) were added 
to the cell culture medium. Vehicle (DMSO) or inhibitors for p38 MAPK (SB203580, 10 µM), JNK 
(SP600125, 10 µM), ERK1/2 (PD98059, 10 µM), phosphatidylinositol 3-kinase (wortmannin, 1 µM) 
or NF-κB (Bay 11–7085, 10 µM) were added to rat lymphocytes 2 h before the addition of IC or SDS. 
Cytokines were measured by ELISA in the 24 h supernatant. Data are represented as mean ± SEM 
and are representative of two independent experiments (n = 3). * p < 0.05 vs. the corresponding 
Control group; + p < 0.05 vs. the corresponding Basal (no inhibitor) group. 
3. E fects of i munoglobulin o centrate (IC) and spray dried serum (SDS) on the production
of TNF (A), IFN-γ (B), and IL-10 (C) by rat lymphocytes. IC and SDS (10 mg/mL) were added to the
cell culture medium. Vehicle (DMSO) or inhibitors for p38 MAPK (SB203580, 10 µM), JNK (SP600125,
10 µM), ERK /2 (PD98059, 10 µM), ph sphatidylinositol 3-kinase (wortmannin, 1 µM) or NF-κB
(Bay 11–7085, 10 µM) were added to rat lymphocytes 2 h befor the addition of IC or DS. Cytokines
were measured by ELISA in the 24 h supernatant. Data are represented as mean ± SEM and are
representative of two independent experiments (n = 3). * p < 0.05 vs. the corresponding Control
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Figure 4. Effects of immunoglobulin concentrate (IC) and spray dried serum (SDS) on the production
of TNF (A) and IL-10 (B) by rat monocytes. IC and SDS (10 mg/mL) were added to the cell culture
medium and cytokines were measured in the supernatant after 24 h by ELISA. Vehicle (DMSO) or
inhibitors for p38 MAPK (SB203580, 10 µM), JNK (SP600125, 10 µM), ERK1/2 (PD98 59, 10 µM),
phosphatidylinositol 3-kinase (wortmannin, 1 µM), or NF-κB (Bay 11–7085, 10 µM) were added
to monocytes 2 h before the addition of IC or SDS. Data are represented as mean ± SEM and are
representative of two independent experiments (n = 3). * p < 0.05 vs. the corresponding Control
group; + p < 0.05 vs. the corresponding Basal (no inhibitor) group.
3.1.3. Signal Transduction Pathways Involving NF-κB, MAPK, AKT, or RAGE Do Not
Contribute to Cytokine Regulation by IC or SPD in Spleen Cells
Next, we studied the molecular mechanisms involved in the observed responses usi g
inhibitors of different sig al transduction molecules involved in NF-κB, MAPK, AKT, or
RAGE pathways (Figures 3–5). As expected, the inhibitors downregulated basal cytokine
production to various degrees. Nevertheless, inhibitors failed to counteract the effects of
IC or SDS in splenocytes, T lymphocytes, or monocytes, indicating that these pathways are
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not involved in the effect. Since NF-κB is a key factor in the regulation of inflammation
we further ruled out its involvement characterizing the effect of both products on p65
translocation to the nucleus, however, no induction was observed (Figure 5D).
3.1.4. Induction of IL-10 Is Not Linked to TNF Inhibition by IC in Spleen Cells
It has been described that the stimulation of CD40 by T lymphocyte membrane-
bound CD40L may induce IRAK1 and subsequently the production of IL-10. In turn,
IL-10 may inhibit TNF expression by inducing the degradation of its mRNA [34]. To test
the involvement of this pathway we cultured splenocytes in the presence of IC or SDS
plus an inhibitor of IRAK1/4 (Figure 6A) or the CD40L-blocking antibody (Figure 6B).
Neither of these molecules restored the production of TNF. In addition, the impact of an
IL-10 blocking antibody on IC-induced TNF modulation was tested using three different
concentrations of the former (1, 2, or 4 µg/mL, Figure 6C, left). An almost complete IL-10
blockade was achieved in all cases in the absence of IC (Figure 6C, right), resulting in
a slight upregulation of TNF release, indicating a significant (albeit minor) modulation
under LPS stimulation in splenocytes. Addition of IC resulted in the expected inhibition of
TNF, which was associated with a slight enhancement of IL-10 production. However, IL-10
blockade had no effect on TNF downregulation by IC. Of note, IL-10 levels were higher in
the medium of IC-treated cells.
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Figure 5. Effects of immunoglobulin concentrate (IC) and spray dried serum (SDS) on the production
of TNF (A), IFN-γ (B), and IL-10 (C) by rat plenocytes. IC or SDS (10 mg/mL) were added to the
cell culture medium. Vehicle (DMSO) or inhibitors for p38 MAPK (SB203580, 10 µM), JNK (SP600125,
10 µM), ERK1/2 (PD98059, 10 µM), phosphatidylinositol 3-kinase (wortmannin, 1 µM) or NF-κB (Bay
11–7085, 10 µM) were added to rat splenocytes 2 h before the addition of IC or SDS and cytokines
were measured by ELISA in the 24 h supernatant. (D) Effect of IC and SDS on NF-κB p65 translocation
to the nucleus. Splenocytes were incubated with IC and SDS for 15 minutes and nuclear content was
extracted for p65 detection by ELISA. Data are represented as mean ± SEM and are representative of
two independent experiments (n = 3). * p < 0.05 vs. the corresponding Control group; + p < 0.05 vs.
the corresponding Basal (no inhibitor) group.
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Figure 6. Involve e t of IL-10 on the inhibition of TNF production by immunoglobulin concentrate
(IC) and spray dried serum (SDS) in rat splenocytes. (A) Effect of NF-κB and IRAK1/4 inhibitors
on TNF production. Bay 11-7082 (10 µM) and the IRAK 1/4 inhi itor 1 (10 µM) were added to the
cell culture medium together with SDS and IC for 48 h. (B) Effect of a blocking anti-CD154 antibody
on TNF production, following the same protocol. (C) Effect of a blocking anti-IL-10 antibody
(1, 2 or 4 µg/mL) on TNF and IL-10 secretion, following the same protocol. (D) Evaluation of IC
immunoreactivity by rat IL-10 ELISA and blockade by rat anti-IL-10 antibody. IC (10 mg/mL) was
measured with a rat ELISA as described in Materials and Methods and the signal compared with
that of the rat IL-10 ELISA standard (1250 pg/mL). The effect of incubation for 4 h at 37 ◦C with a
blocking anti-IL10 antibody (1 µg/mL) was also assessed. RPMI medium without FBS was used in
all cases. Cytokines were measured in the culture medium by ELISA. + p < 0.05 vs. the corresponding
Basal group; * p < 0.05 vs. Control group.
One possible explanation for these results is that IC contains bioactive IL-10 of porcine
origin. To explore this possibility IL-10 immunoreactivity was measured in IC with a rat
IL-10 ELISA (Figure 6D). A positive signal was detected, which was not inhibited by the
anti-IL-10 antibody, unlike the rat IL-10 standard. This suggests that IC does contain porcine
IL-10, but this needs confirmation and quantification by specific antibody (not available).
4. Discussion
Using IEC18 rat ileal cells as model intestinal epithelial cells we have described
that both protein concentrates upregulate GROα and MCP-1 chemokine production in
basal conditions, an effect that is mediated by NF-κB and requires MyD88. MyD88 is an
adaptor molecule for innate immune IL-1 receptors and all TLRs except TLR3, linking these
receptors to IRAK, that in turn activates NF-κB and MAPK. In turn, TLR4 was required
for IC but not SDS effects. In this regard our results indicate that IC/SDS may similarly
elicit GROα and MCP-1 secretion acting from the luminal side in vivo. This is contingent
on these products reaching the intestine in sufficiently high concentrations. ICs have been
demonstrated to be digested only partially and to reach the distal sites of the gastrointestinal
tract [26–28]. The immunomodulatory activity of other proteins has also been shown to
be partly resistant to digestion [32,35]. Are the concentrations tested in our study relevant
in vivo? Quantitatively speaking, a supplementation of 80 g/kg and 22.7 mg/kg diet for
SDS and IC as in the in vivo study of Pérez-Bosque et al. [9] and others would result in 240
and 68.1 mg/day at the standard intake of 3 g/d in mice. If no degradation was produced,
this would be expected to produce concentrations of approximately 1200 and 340.5 mg/mL
in the colon (assuming a volume of 0.3 mL). In other words, only around 3% of the intake
of IC is required to yield concentrations shown to be active in the present in vitro study.
Interestingly, porcine SDS has been recently shown in a multi-OMICS study to modulate
skin barrier function in teleost fish when given as a nutritional supplement [36]. This study
not only supports the bioactivity of the components of this product beyond the epithelial
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layer, but shows an effect comparable to that in the intestinal mucosa, which shares a
number of characteristics with the skin as a biological barrier.
Stimulation of MyD88-related receptors and NF-κB in enterocytes by different molecules
serves a series of complex immunomodulatory and physiological regulatory purposes,
including not only cytokine/chemokine secretion, but also the regulation of apoptosis and
proliferation in IECs [37] and antibacterial peptide secretion [38–40]. Thus it is likely that
other MyD88/NFκB-dependent beneficial responses may be at play in IC/SDS protective
effects at the epithelial level, although this will require additional experiments. Thus the
intestinal epithelial effects of SDS and IC are consistent with reinforcement of mucosal
barrier function and overall protection against inflammation [41,42]. This effect resembles
microbiota-derived signals that, sensed to a great extent via TLRs, contribute significantly to
the regulation of epithelial cell turnover and resistance to mucosal injury [43]. Importantly,
TLR4 KO mice exhibit increased sensitivity to experimental colitis, along with various
other TLRs and related receptors and signaling molecules [42]. Similarly, a number of
compounds with functional foods properties have been described to act as TLR4 ligands or
activators having no deleterious effect in vivo (such as colitis) while limiting experimental
intestinal inflammation, including bovine glycomacropeptide, nonabsorbable carbohy-
drates or active hexose correlated compound [33,44–52]. As indicated, this is precisely the
case also for these porcine protein concentrates in vivo [2,8,9].
On the other hand, SDS and IC were found to consistently inhibit TNF production by
rat splenocytes, T lymphocytes, and monocytes. This effect was associated with increased
IL-10 and IFN-γ production in splenocytes and T lymphocytes, while IL-10 was inhibited
in monocytes. TNF is a target for anti-inflammatory therapies, particularly anti-TNF anti-
bodies. Because TNF inhibition effects were so consistent, we aimed to better characterize
the molecular pathways involved, finding that NF-κB, MAPKs, RAGE, or AKT were not
involved. This was also the case for IFN-γ production. It has been described that T cells
down-regulate monocyte TNF production by IRAK1-mediated IL-10 expression [53]. TNF
decrease was however shown to be totally independent of IRAK4 inhibition and also to
be not reversed by CD154/CD40L blockade (which actually enhanced TNF lowering by
IC). Perhaps more importantly, the effect on TNF was unchanged by addition of a blocking
antibody against IL-10 itself (the latter documented only for IC). It is noteworthy that in
this experiment while the anti-IL-10 antibody virtually eliminated IL-10 from the culture
medium in the control (i.e., LPS only) group, it did so only by ~50% in the IC groups,
despite the fact that IL-10 levels were quite similar in both. One possible explanation is
that IC may contain biologically active porcine IL-10, which may be unaffected by the
anti-IL-10 antibody but detected by the rat IL-10 ELISA. Such cross-species sensitivity is not
contemplated in either the ELISA assay or the anti-IL10 antibody. However, at 10 g/L IC
does show a positive signal in the rat IL-10 ELISA, which is not affected by the anti-IL10 an-
tibody. Thus this is a possible mechanism. Since TNF is a pivotal proinflammatory cytokine
in intestinal inflammation, it is possible that SDS/IC may act in part by downregulating
this key player in the inflammatory response. This would obviously require access of these
products to the mucosal milieu. This remains uncertain at this point, but it is a mechanism
probably facilitated by the disruption of the mucosal barrier in an inflammatory context.
It is interesting to comment the similar composition of porcine concentrates and
that of intravenous immunoglobulin treatment (IVIg) therapy. This therapy consists in
the administration of human immunoglobulins (mainly IgG) and has proven effective
in the treatment of a wide variety of autoimmune and chronic inflammatory diseases.
Unfortunately, the mechanism of action of IVIg remains poorly characterized, although
it is thought to involve a complex interplay with the host immune system [54]. Of note,
a similar approach has been aplied with animal protein concentrates by the oral route.
Recently this strategy has been tried in noncritical COVID19 patients (ClinicalTrials.gov
Identifier: NCT04682041, accessed on 4 March 2021).
Our research group has previously shown that several protein products can directly
regulate the immune response of intestinal epithelial cells, monocytes, and lymphocytes.
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Among these products are protein fractions, a protein hydrolysate from algae, and bovine
glycomacropeptide, a 64 amino acid peptide that is part of κ-casein as obtained in whey in
the cheese-making process [33,46,49,50,55–57]. These products induce the production of
IL-10 by monocytes/macrophages and lymphocytes by way of NF-κB and MAPK (p38 and
JNK) activation [32,50,55]. At the same time, they inhibit the production of proinflammatory
cytokines by monocytes/macrophages. Thus, there is overlap between the effects of these
protein products in vitro.
Our data provide new evidence about the possible mechanism whereby SDS and
IC may protect against colitis and reinforce barrier function. As discussed, the efficacy
of porcine protein concentrates when administered by the oral route in vivo depends on
the capacity to withstand digestion and, for nonepithelial actions, to access the intestinal
mucosa. Protein concentrates may have additional mechanisms, such as modulation of
the microbiota, adsorption/neutralization of toxins, etc. In fact, prebiotic effects have been
documented in the case of porcine SDP [58].
5. Conclusions
In conclusion, our results indicate that our hypothesis, i.e., dietary plasma protein
concentrates from animal origin may have immunomodulatory activity, is correct. Serum
protein concentrates were shown to exert complex biological immunomodulatory actions
in vitro. One is represented by the activation of MyD88 and NFκB in IECs. This effect may
contribute to the reinforcement of the intestinal barrier function. The actions on splenocytes
(inducing IL-10 and inhibiting TNF) may result in anti-inflammatory effects.
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